Yeast News and Research

RSS

Synthetic biologists develop versatile platform for targeted drug delivery

In recent years, cell and gene therapies have shown significant promise for treating cancer, cystic fibrosis, diabetes, heart disease, HIV/AIDS and other difficult-to-treat diseases.

27 Nov 2023

Ingenza and Phibro Ethanol accelerate the green fuel transition

Ingenza and Phibro Ethanol – a division of Phibro Animal Health Corporation – have joined forces to engineer a novel yeast strain that will increase yield in the commercial production of bioethanol under both challenging and conventional environmental conditions, further driving the switch to clean biofuels.

From Ingenza Ltd 24 Nov 2023

Green tea-silver nanoparticles: A promising weapon against superbugs

Once upon a time, people believed to be invincible against bacterial diseases, thanks to the antibiotics. Does this sound like a fairy tale? By all means! Nothing could be further from the truth.

17 Nov 2023

New research explores the unique effects of ADHD medications on Drosophila brain cells

The effect of two drugs used for the treatment of attention-deficit/hyperactivity disorder.

15 Nov 2023

Genetically engineered yeast cells produce natural plant product for schizophrenia treatment

An international team of researchers has demonstrated that genetically engineered yeast cells can produce the natural plant product alstonine, which has shown positive effects in treating schizophrenia.

10 Nov 2023

Omicron variant BA.2.86 spreads faster, but current antivirals hold the line

Researchers discover the BA.2.86 Omicron lineage with higher transmission potential than current dominant strains, yet show that existing antivirals remain effective. Despite its higher infectivity, BA.2.86 exhibits lower pathogenicity in hamsters, indicating decreased replication capacity may lead to less severe infections.

7 Nov 2023

New gene editing method creates first mice with human-like COVID-19

Researchers have genetically engineered the first mice that get a human-like form of COVID-19, according to a study published online November 1 in Nature.

1 Nov 2023

How next-gen sequencing is changing antibody drug discovery

New study outlines how next-generation sequencing (NGS) and machine-learning methods can revolutionize antibody discovery, particularly against SARS-CoV-2. The research demonstrates that NGS provides greater epitopic and paratopic diversity, enabling more effective identification and prioritization of therapeutic antibodies.

31 Oct 2023

New bivalent vaccine shows promising results against key fish pathogens

The efficacy of a bivalent vaccine against Aeromonas hydrophila (A. hydrophila) and Streptococcus agalactiae (S. agalactiae).

30 Oct 2023

Fungi used to produce food products have potential probiotic effects on gut inflammation

Many fungus strains have been used and selected by the food industry for their capacities to ferment, produce flavors or produce heterologous molecules.

26 Oct 2023

What's really in your kombucha and kefir?

Researchers have delved into the bacterial diversity of 47 different fermented foods, revealing significant variations in microbial richness and composition. The study highlights that foods like kombucha and kefirs have high microbial diversity, while plant-based yogurt alternatives and fermented vegetables show lower levels.

24 Oct 2023

Study sheds light on role of gut fungi in severe COVID-19 and long COVID

Certain gut-dwelling fungi flourish in severe cases of COVID-19, amplifying the excessive inflammation that drives this disease while also causing long-lasting changes in the immune system, according to a new study led by investigators at Weill Cornell Medicine and NewYork-Presbyterian.

24 Oct 2023

Researchers study how cells adapt to stressful and complex environments

Imagine the life of a yeast cell, floating around the kitchen in a spore that eventually lands on a bowl of grapes. Life is good: food for days, at least until someone notices the rotting fruit and throws them out.

16 Oct 2023

Study reveals molecular mechanism behind new DOT1L-related disorder

A study from the laboratory of Dr. Hugo J. Bellen, a distinguished service professor at Baylor College of Medicine and a principal investigator at the Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital, has discovered that gain-of-function variants in the DOT1L gene cause a new disorder.

13 Oct 2023

Stress-induced ribosome dysregulation may underlie depression

A group of ribosomal protein genes connects animal models of depression to human patients with major depressive disorder.

10 Oct 2023

Graphene oxide offers a promising new approach to treating Alzheimer's disease

A probable early driver of Alzheimer's disease is the accumulation of molecules called amyloid peptides. These cause cell death, and are commonly found in the brains of Alzheimer’s patients. Researchers at Chalmers University of Technology, have now shown that yeast cells that accumulate these misfolded amyloid peptides can recover after being treated with graphene oxide nanoflakes.

9 Oct 2023

New insights into how neutrophils fight Candida albicans infection

Umeå University researchers, Sweden, unveil how the most common white blood cells, neutrophils, counter Candida albicans toxin stopping its tracks.

5 Oct 2023

Graphene oxide nanoflakes may help treat Alzheimer's disease

A probable early driver of Alzheimer's disease is the accumulation of molecules called amyloid peptides. These cause cell death, and are commonly found in the brains of Alzheimer's patients.

4 Oct 2023

Yeast in the gut linked to Crohn's disease inflammation, opening new doors for treatment

New study in Nature Medicine links yeast cells in the gastrointestinal tract to abnormal immune responses causing inflammation in Crohn's disease patients. The research suggests that these yeast-reactive T-cells could be a potential therapeutic target, offering new avenues for treatment.

27 Sep 2023

Kombucha tea shows promise in lowering blood sugar levels for type 2 diabetics

A recent clinical trial conducted at Georgetown University Hospital suggests that kombucha tea may hold potential as an anti-hyperglycemic agent, reducing fasting blood glucose levels in adult patients with type 2 diabetes. While the results are promising, further research with larger sample sizes is needed to solidify the health benefits of kombucha in managing diabetes.

25 Sep 2023